AU2022261504A1 - Method for treating acute respiratory distress syndrome (ards) in specific patients using mesenchymal lineage precursor or stem cells - Google Patents

Method for treating acute respiratory distress syndrome (ards) in specific patients using mesenchymal lineage precursor or stem cells Download PDF

Info

Publication number
AU2022261504A1
AU2022261504A1 AU2022261504A AU2022261504A AU2022261504A1 AU 2022261504 A1 AU2022261504 A1 AU 2022261504A1 AU 2022261504 A AU2022261504 A AU 2022261504A AU 2022261504 A AU2022261504 A AU 2022261504A AU 2022261504 A1 AU2022261504 A1 AU 2022261504A1
Authority
AU
Australia
Prior art keywords
subject
mlpscs
cells
level
million
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022261504A
Other languages
English (en)
Inventor
Silviu Itescu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mesoblast International SARL
Original Assignee
Mesoblast International SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021901214A external-priority patent/AU2021901214A0/en
Application filed by Mesoblast International SARL filed Critical Mesoblast International SARL
Publication of AU2022261504A1 publication Critical patent/AU2022261504A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2022261504A 2021-04-23 2022-04-22 Method for treating acute respiratory distress syndrome (ards) in specific patients using mesenchymal lineage precursor or stem cells Pending AU2022261504A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
AU2021901214A AU2021901214A0 (en) 2021-04-23 Method for treating acute respiratory distress syndrome (ARDS) using mesenchymal lineage precursor or stem cells
AU2021901214 2021-04-23
AU2021902180 2021-07-15
AU2021902180A AU2021902180A0 (en) 2021-07-15 Method for treating acute respiratory distress syndrome (ARDS) using mesenchymal lineage precursor or stem cells
AU2022900260 2022-02-09
AU2022900260A AU2022900260A0 (en) 2022-02-09 Method for treating acute respiratory distress syndrome (ARDS) in specific patients using mesenchymal lineage precursor or stem cells
AU2022900372 2022-02-18
AU2022900372A AU2022900372A0 (en) 2022-02-18 Method for treating acute respiratory distress syndrome (ARDS) using mesenchymal lineage precursor or stem cells
PCT/IB2022/053762 WO2022224206A1 (en) 2021-04-23 2022-04-22 Method for treating acute respiratory distress syndrome (ards) in specific patients using mesenchymal lineage precursor or stem cells

Publications (1)

Publication Number Publication Date
AU2022261504A1 true AU2022261504A1 (en) 2023-11-30

Family

ID=81585202

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2022261504A Pending AU2022261504A1 (en) 2021-04-23 2022-04-22 Method for treating acute respiratory distress syndrome (ards) in specific patients using mesenchymal lineage precursor or stem cells
AU2022260822A Pending AU2022260822A1 (en) 2021-04-23 2022-04-22 Method for treating acute respiratory distress syndrome (ards) using mesenchymal lineage precursor or stem cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022260822A Pending AU2022260822A1 (en) 2021-04-23 2022-04-22 Method for treating acute respiratory distress syndrome (ards) using mesenchymal lineage precursor or stem cells

Country Status (8)

Country Link
US (2) US20240207323A1 (https=)
EP (2) EP4326294A1 (https=)
JP (2) JP2024516172A (https=)
KR (2) KR20240001172A (https=)
AU (2) AU2022261504A1 (https=)
BR (2) BR112023021840A2 (https=)
CA (2) CA3216129A1 (https=)
WO (2) WO2022224206A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120087868A1 (en) 2010-10-08 2012-04-12 Gabriele Todd Nanoparticle-loaded cells
SG11202004680UA (en) 2017-11-22 2020-06-29 Mesoblast Int Sarl Cellular compositions and methods of treatment i

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
BR112021024310A2 (pt) * 2019-06-05 2022-02-15 Univ Emory Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus

Also Published As

Publication number Publication date
BR112023021825A2 (pt) 2024-02-06
JP2024516173A (ja) 2024-04-12
US20240197787A1 (en) 2024-06-20
CA3216129A1 (en) 2022-10-27
JP2024516172A (ja) 2024-04-12
WO2022224207A1 (en) 2022-10-27
EP4326294A1 (en) 2024-02-28
KR20240001172A (ko) 2024-01-03
AU2022260822A1 (en) 2023-11-30
EP4326295A1 (en) 2024-02-28
KR20240001173A (ko) 2024-01-03
US20240207323A1 (en) 2024-06-27
CA3216121A1 (en) 2022-10-27
WO2022224206A1 (en) 2022-10-27
BR112023021840A2 (pt) 2024-02-06

Similar Documents

Publication Publication Date Title
WO2021198454A1 (en) Method for treating hyperinflammation using mesenchymal lineage precursor or stem cells
US20230097931A1 (en) Method for treating chronic graft versus host disease
US20240197787A1 (en) Method for treating acute respiratory distress syndrome (ards) in specific patients using mesenchymal lineage precursor or stem cells
US20230293589A1 (en) Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
AU2021403025A1 (en) Method of treating progressive heart failure in subjects with class ii heart failure
AU2023389701A1 (en) Method of treating inflammation with cellular compositions
CN119563020A (zh) 经低温保存的中间体以及用于其的效力测定
WO2023119239A1 (en) Method of treating severe graft versus host disease
CN117715649A (zh) 使用间充质谱系前体细胞或干细胞治疗特定患者的急性呼吸窘迫综合征(ards)的方法
WO2025046491A1 (en) Third line treatment for gvhd
KR20260061190A (ko) GvHD에 대한 3차 치료
CN121985953A (en) Three-wire therapy for the treatment of GvHD
EP4264275A2 (en) Method of treating progressive heart failure in subjects with class ii heart failure
EP4433070A1 (en) Method of treating progressive heart failure in subjects at high risk of poor outcomes
WO2023092043A1 (en) Method of treating progressive heart failure in subjects at high risk of poor outcomes